|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | REVIEW ARTICLE ON USE OF ESKETAMINE FOR THE TREATMENT OF PATIENTS WITH TREATMENT RESISTANT DEPRESSION |
| Authors Name: | MRS. ARTHI C , PROF. PRABAVATHY S , MR. SATHIYASEELAN A |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_213580
|
| Published Paper Id: | IJNRD2402123 |
| Published In: | Volume 9 Issue 2, February-2024 |
| DOI: | |
| Abstract: | Treatment-resistant depression (TRD) is a serious difficulty in mental health treatment, needing novel and effective treatments. Esketamine, the S-enantiomer of ketamine, has emerged as an exciting new therapy for TRD. Clinical trials have shown that it is helpful in delivering quick relief for TRD patients, with significant improvements shown within hours to days of dosing. The quick commencement of action is especially important in circumstances where standard antidepressants can take weeks to show therapeutic effects. Esketamine is a viable therapy alternative for TRD patients, providing immediate and strong antidepressant effects through a novel mechanism of action. |
| Keywords: | Esketamine, TRD, S-enantiomer |
| Cite Article: | "REVIEW ARTICLE ON USE OF ESKETAMINE FOR THE TREATMENT OF PATIENTS WITH TREATMENT RESISTANT DEPRESSION", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.9, Issue 2, page no.b168-b172, February-2024, Available :http://www.ijnrd.org/papers/IJNRD2402123.pdf |
| Downloads: | 000118751 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2402123 Registration ID: 213580 Published In: Volume 9 Issue 2, February-2024 DOI (Digital Object Identifier): Page No: b168-b172 Country: Puducherry, Puducherry, India Research Area: Health Science Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2402123 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2402123 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn